- Home
- ODD vs AMRX Comparison
ODD vs AMRX Comparison
Compare ODD & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | AMRX |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ODD | AMRX |
|---|---|---|
| Price | $42.18 | $12.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $69.45 | $13.25 |
| AVG Volume (30 Days) | 689.5K | ★ 1.9M |
| Earning Date | 11-19-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.01 | N/A |
| EPS | ★ 1.79 | 0.02 |
| Revenue | $780,758,000.00 | ★ $2,934,959,000.00 |
| Revenue This Year | $26.15 | $9.99 |
| Revenue Next Year | $20.55 | $6.67 |
| P/E Ratio | ★ $23.40 | $690.00 |
| Revenue Growth | ★ 25.80 | 9.50 |
| 52 Week Low | $35.30 | $6.69 |
| 52 Week High | $79.18 | $13.01 |
Technical Indicators
Market Signals| Indicator | ODD | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 68.02 |
| Support Level | $41.36 | $12.75 |
| Resistance Level | $44.09 | $12.53 |
| Average True Range (ATR) | 1.63 | 0.29 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 16.56 | 98.31 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.